LABA Long acting beta-agonist LAMA Long acting muscarinic antagonist LS Least squares LTRA Leukotriene receptor antagonist mAb Monoclonal antibody MedDRA Medical Dictionary for Regulatory Activities MMRM Mixed effect model for repeated measures NB Negative binomial NIH National Institute of Health OCS Oral corticosteroid PEFR Peak expiratory flow rate PFT Pulmonary function tests PI Product Information PIP Paediatric investigation plan PCS Potentially clinically significant PD Pharmacodynamic PK Pharmacokinetic % predicted Actual FEV1 divided by standard predicted FEV1 times 100% FEV1 PopPK Population pharmacokinetic PP Per protocol PT Preferred Term RMP Risk Management Plan RR Rate ratio
LABA Long acting beta-agonist LAMA Long acting muscarinic antagonist LS Least squares LTRA Leukotriene receptor antagonist mAb Monoclonal antibody MedDRA Medical Dictionary for Regulatory Activities MMRM Mixed effect model for repeated measures NB Negative binomial NIH National Institute of Health OCS Oral corticosteroid PEFR Peak expiratory flow rate PFT Pulmonary function tests PI Product Information PIP Paediatric investigation plan PCS Potentially clinically significant PD Pharmacodynamic PK Pharmacokinetic % predicted FEV1 Actual FEV1 divided by standard predicted FEV1 times 100% PopPK Population pharmacokinetic PP Per protocol PT Preferred Term RMP Risk Management Plan RR Rate ratio
auspar-reslizumab-180605-cer.docx